Saturday, December 13, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Kerrisdale Capital maintains bearish position on Altimmune ALT

Elaine Mendonca by Elaine Mendonca
February 26, 2024
in Breaking News
0
Financing and finances
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

As of February 26, 2024, Kerrisdale Capital has reiterated to Benzinga their position on Altimmune (ALT) – they remain bearish on the stock. This suggests that Kerrisdale Capital is sticking to their belief that Altimmune’s performance in the market will not meet expectations, as they continue to hold a short position on the company.

ALT Stock Surges 29.08% on February 26, 2024: Potential for Significant Gains in Stock Market

On February 26, 2024, ALT stock had an impressive performance as it traded near the top of its 52-week range and above its 200-day simple moving average. The price of ALT shares increased by $2.68 since the market last closed, representing a significant 29.08% rise. The stock opened at $10.42 on that day, which was $1.22 higher than its previous close, indicating positive momentum for ALT stock. Investors were likely encouraged by the price momentum of ALT stock as it continued to climb higher throughout the trading session. The 29.08% increase in share price reflected growing confidence in the company’s performance and future prospects. ALT’s strong performance on February 26, 2024, demonstrated the potential for significant gains in the stock market. Overall, the positive price momentum and significant increase in share price highlighted the potential for growth and success in ALT stock. Investors will continue to monitor the company’s performance and market trends to make informed decisions about their investment strategies.

ALT Stock Performance Analysis: Mixed Results on February 26, 2024

On February 26, 2024, ALT stock experienced mixed performances based on the data provided by CNN Money. The company’s total revenue for the past year was reported at -$68.00K, indicating a significant decrease of 101.54% compared to the previous year. However, in the third quarter of the same year, the total revenue surged to $362.00K, marking an impressive increase of 5933.33% since the last quarter.

Similarly, ALT’s net income showed contrasting trends over the same period. The net income for the past year was reported at -$84.71M, showing a slight increase of 12.75% compared to the previous year. However, in the third quarter, the net income decreased to -$20.67M, representing a decline of 28.7% since the last quarter.

The earnings per share (EPS) for ALT stock also exhibited diverging patterns. The EPS for the past year was reported at -$1.81, indicating an increase of 23.24% compared to the previous year. However, in the third quarter, the EPS decreased to -$0.39, marking a decline of 21.65% since the last quarter.

Overall, ALT stock’s performance on February 26, 2024, reflected a mix of positive and negative trends in terms of total revenue, net income, and earnings per share. Investors and analysts will likely closely monitor the company’s financial results in the upcoming quarters to assess its future growth prospects and potential investment opportunities.

Tags: ALT
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Stock Bull Market

Oppenheimer Analyst Martin Yang Reaffirms Positive Outlook on Sony Group with Outperform Rating and 108 Price Target

Healthcare cloud based

Agilitis Stock Soars as THL Partners Acquires Healthcare Technology Firm

Finances

Leerink Partners Analyst Initiates Coverage on Labcorp with Outperform Rating and 260 Price Target

Recommended

Varonis Stock

Varonis Stock Positioned for Growth Amid AI and Cloud Expansion

2 months ago
Omv Stock

OMV Shares Face Conflicting Signals as Management and Analysts Clash

4 weeks ago
Cardano Stock

Cardano’s Pivotal Moment: Whale Exodus Meets Privacy Innovation

1 month ago
Strategy Stock

Bitcoin Specialist Strategy Faces Investor Skepticism Despite Record Profits

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Immunovant Secures Major Funding to Advance Key Drug Candidate

UnitedHealth Faces Mounting Legal and Financial Pressures

The Trade Desk: A Premium Stock Under Scrutiny

Amazon’s Aggressive AI Expansion: Balancing Massive Investment with Market Expectations

Purple Innovation Stock Under Scrutiny Amid Strategic Review

Uranium Energy’s Strategic Pivot: Building Inventory Amid Policy Shifts

Trending

P10 Stock
Earnings

P10 Shares Navigate a Week of Market Turbulence

by Robert Sasse
December 13, 2025
0

The stock of P10 has experienced significant volatility in recent trading sessions. After a period of notable...

CureVac Stock

CureVac Shareholders Face a Critical Deadline

December 13, 2025
Regional Management Stock

Conflicting Cues Emerge for Regional Management Investors

December 13, 2025
Immunovant Inc Stock

Immunovant Secures Major Funding to Advance Key Drug Candidate

December 13, 2025
Unitedhealth Stock

UnitedHealth Faces Mounting Legal and Financial Pressures

December 13, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • P10 Shares Navigate a Week of Market Turbulence
  • CureVac Shareholders Face a Critical Deadline
  • Conflicting Cues Emerge for Regional Management Investors

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com